Vishal Khairnar, PhD

Vishal Khairnar, PhD, is a Senior Scientist II at Cytovia Therapeutics, where responsibilities include leading in vivo and in vitro studies in pharmacology development and overseeing a team for evaluating the NK/iNK engager platform. Vishal has also served as a Scientific Advisor at Ymmunobio and conducted postdoctoral research at Dana-Farber Cancer Institute and Harvard Medical School, focusing on CAR-T cell constructs and oncogenic pathways in leukemia. Previous experience includes roles at the Leukemia & Lymphoma Society, City of Hope, and Universitätsklinikum Essen, contributing to research on drug resistance and immune activation. Vishal holds a PhD in Molecular and Cellular Immunology and has an extensive background in biotechnology, with earlier roles as a Research Associate at the National Chemical Laboratory.